scholarly journals Assessment of nutritionnal status and nutrition in patients with arterial hypertension

2020 ◽  
pp. 686-694
Keyword(s):  
Internal Medicine ◽  
Metabolic Syndrome ◽  
Nutritional Status ◽  
Arterial Hypertension ◽  
Visceral Obesity ◽  
Diet Therapy ◽  
Composition Analysis ◽  
Hip Circumference ◽  
Hypertensive Patients ◽  
Treatment Of Hypertension

INTRODUCTION. The factors predisposing to the occurrence of cardiovascular event are mainly age, visceral obesity and metabolic syndrome. To our knowledge, there are no studies assessing both the nutritional status and diet of hypertensive patients in Poland. AIM. Our aim is the assessment of the diet and nutritional status of patients with hypertension. MATERIAL AND METHODS. This study included 50 patients (K: 32, M: 18) with hypertension admitted to the Department of Internal Medicine at the Heliodor Święcicki Clinical Hospital in Poznan. Anthropometric measurements (waist and hip circumference), and body composition analysis were used to assess nutritional status. Additionally, we carried out the nutritional interview. RESULTS. We observed that among hypertensive patients, overweight occurred in 18% and obesity (definition based on BMI) in 48% of all patients. We found that visceral obesity (definition based on WHR) concerns 76% of patients. Moreover, we diagnosed a metabolic syndrome in 56% of patients. None of the patients treated the DASH diet, especially recommended for the treatment of hypertension. What’s more, as many as 50% of hypertensive patients used salt for meals twice a day. CONCLUSIONS. In patients with hypertension the frequent occurrence of obesity and metabolic syndrome may to a large extent result from the dietary support deviating from the rational diet. There is a need to educate patients with arterial hypertension in the field of non-pharmacological treatment methods, especially diet therapy

Increased hip circumference in individuals with metabolic syndrome affects serum nesfatin-1 levels

2019 ◽  
Vol 96 (1140) ◽  
pp. 600-605
Author(s):  
Tuba Tekin ◽  
Betül Çiçek ◽  
Nurefşan Konyalıgil ◽  
İnayet Güntürk ◽  
Cevat Yazıcı ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Body Weight ◽  
Nutritional Status ◽  
Blood Parameters ◽  
Control Group ◽  
Case Group ◽  
Hip Circumference ◽  
Anthropometric Indices ◽  
The Relationship ◽  
Positive Significant Correlation

BackgroundThis case–control study was conducted to investigate the relationship between serum nesfatin-1 levels and nutritional status and blood parameters in patients diagnosed with metabolic syndrome.MethodsThirty patients (case) diagnosed with metabolic syndrome according to National Cholesterol Education Program-Adult Treatment Panel III criteria were included. Thirty healthy subjects (control) matched with patients with metabolic syndrome in terms of age, gender and body mass index were included. Three-day food consumption records were obtained. Anthropometric indices were measured and body composition was determined by bioelectrical impedance method. Biochemical parameters and serum nesfatin-1 levels were measured after 8 hours of fasting.ResultsSerum nesfatin-1 levels were 0.245±0.272 ng/mL in the case group and 0.528±0.987 ng/mL in the control group (p>0.05). There was a positive significant correlation between serum nesfatin-1 levels and body weight, waist and hip circumferences in the case group (p<0.05). Each unit increase in hip circumference measurement affects the levels of nesfatin by 0.014 times. In the control group, there was a positive significant correlation between body weight and serum nesfatin-1 levels (p<0.05). A significant correlation was detected between HbA1c and serum nesfatin-1 levels in the case group (p<0.05). A significant relationship was detected between dietary fibre intake and the serum nesfatin-1 levels in the case group (p<0.05).ConclusionsAnthropometric indices and blood parameters were correlated with serum nesfatin-1 levels in patients with metabolic syndrome. More clinical trials may be performed to establish the relationship between serum nesfatin-1 levels and nutritional status.

scholarly journals Comorbid pathology and prognosis of breast cancer in women in menopause.

2018 ◽  
Vol 96 (1) ◽  
pp. 55-59
Author(s):  
Nailya S. Asfandiyarova ◽  
E. P. Kulikov ◽  
A. S. Skopin ◽  
A. N. Demko ◽  
A. A. Nikiforov
Keyword(s):  
Breast Cancer ◽  
Metabolic Syndrome ◽  
Arterial Hypertension ◽  
Visceral Obesity ◽  
Suppressor Cells ◽  
Cancer Prognosis ◽  
Lymph Node Status ◽  
Regional Lymph Nodes ◽  
The Metabolic Syndrome ◽  
Menopausal Women

Comorbid pathology is important in the survival of patients with breast cancer. The main aim of the present study was to investigate prognostic criteria of the 5-year survival menopausal women with breast cancer, including both the classic criteria (age, tumor size, lymph node status, hormonal status) and the presence of comorbid pathology (arterial hypertension, visceral obesity, diabetes mellitus, metabolic syndrome, immunodeficiency). A prospective cohort study included 98 patients with breast cancer (aged 63 ± 9 years, BMI 31.6 ± 4.8 kg/m2). Criteria favorable short-term (5 years) of the cancer prognosis of breast cancer in menopausal women are the size of the tumor less than 5 cm, the absence of metastases in regional lymph nodes, and the absence of the metabolic syndrome, dyslipidemia, high activity of suppressor cells. Age, anthropometric indices (BMI, waist circumference etc.), presence of arterial hypertension do not give information about the 5-year survival rate in breast cancer.

scholarly journals Efficacy of irbesartan in arterial hypertension and metabolic syndrome

2013 ◽  
Vol 10 (2) ◽  
pp. 53-56
Author(s):  
O D Ostroumova ◽  
A A Zykova ◽  
T A Polosova ◽  
O V Bondarets
Keyword(s):  
Metabolic Syndrome ◽  
Angiotensin Ii ◽  
Arterial Hypertension ◽  
Antihypertensive Drugs ◽  
Angiotensin Ii Receptor Blockers ◽  
Efficacy And Safety ◽  
Angiotensin Ii Receptor ◽  
Hypertensive Patients ◽  
Receptor Blockers

The paper gives the data of Russian guidelines for the diagnosis and approaches to treating metabolic syndrome. It considers the choice of antihypertensive drugs in the treatment of hypertensive patients with metabolic syndrome. The benefits of angiotensin II receptor blockers are shown. The results of a number of trials evaluating the efficacy and safety of irbesartan used to manage arterial hypertension in metabolic syndrome are analyzed.

scholarly journals Gut and oral microbiota in patients with arterial hypertension and metabolic syndrome

2020 ◽  
pp. 101-105
Author(s):  
М.В. Яковлева ◽  
В.М. Червинец ◽  
Ю.В. Червинец ◽  
Л.Е. Смирнова
Keyword(s):  
Metabolic Syndrome ◽  
Arterial Hypertension ◽  
Oral Fluid ◽  
Oral Microbiota ◽  
Hypertensive Patients ◽  
E Coli ◽  
Bacillus Spp ◽  
Klebsiella Spp ◽  
Lactobacillus Spp ◽  
Clostridium Spp

Последние годы привлекает внимание роль кишечной микробиоты в патогенезе сердечно-сосудистых заболеваний (ССЗ) и метаболического синдрома (МС). Имеются данные, что метаболиты бактерий кишечника вносят вклад в развитие атеросклероза, АГ, сердечной недостаточности, ожирения и сахарного диабета, способствуют формированию нарушений в системе иммунитета. Изменения кишечного макробиотического пейзажа повышает проницаемость кишечной стенки, способствует развитию эндотоксемии, что играет определенную роль в развитии хронического воспаления в организме, способствуя развитию ожирения и других коморбидных проявлений МС. Цель - изучение особенностей микробиоты кишечника и полости рта у больных артериальной гипертензией (АГ) на фоне МС. Методика. Исследование микробиома фекалий и ротовой жидкости пациентов с АГ и МС проводили с помощью классического бактериологического анализа. Идентификация микроорганизмов осуществлялась по морфологическим, тинкториальным, культуральным и биохимическим свойствам. Результаты. При исследовании фекалий у больных АГ с МС, в сравнении с группой больных АГ, увеличивается частота встречаемости E. coli, Klebsiella spp, выделяются Bacillus spp. Streptococcus spp., Proteus spp., Neisseria spp., S. Aureus, уменьшается частота встречаемости Lactobacillus spp., Bacteroides spp. при отсутствии Bifidobacterium spp. В ротовой жидкости у больных АГ с МС обнаруживаются Clostridium spp., Lactobacillus spp., Klebsiella spp. и в небольшом количестве присутствуют Neisseria spp., Fusobacterium spp. Заключение. В толстом кишечнике у больных АГ с МС отмечается выраженный дисбактериоз с преобладанием условно-патогенных клебсиелл, энтеробактерий, протея, золотистого стафилококка. Микробиом кишечника больных АГ без МС представлен нормальной микрофлорой. В полости рта у больных АГ с МС также преобладают условно-патогенные клостридии, клебсиеллы. Микробиота больных с АГ без МС более многообразна с преобладанием нормофлоры. In recent years, the role of intestinal microbiota in the pathogenesis of cardiovascular diseases (CVD) and metabolic syndrome (MS) has attracted attention. There is evidence that intestinal bacterial metabolites contribute to development of atherosclerosis, hypertension, heart failure, obesity, diabetes, and immune disorders. Changes in the intestinal macrobiotic landscape lead to increased intestinal permeability and endotoxemia, which play a role in chronic inflammation and facilitate development of obesity and other MS comorbidities. Aim. To study features of intestinal and oral microbiota in patients with arterial hypertension (AH) associated with MS. Methods. Study materials were feces and oral fluid of patients with AH and MS where the microbiome was studied with a classical bacteriological analysis. Microorganisms were identified by their morphological, tinctorial, cultural, and biochemical properties. Results. In feces of hypertensive patients with MS as distinct from patients with hypertension, incidences of E. coli and Klebsiella spp. were increased; Bacillus spp., Streptococcus spp., Proteus spp., Neisseria spp., and S. aureus were found; incidences of Lactobacillus spp., and Bacteroides spp. were decreased; and Bifidobacterium spp were absent. In the oral fluid of patients with AH and MS, Clostridium spp., Lactobacillus spp., Klebsiella spp. and small amounts of Neisseria spp. and Fusobacterium spp. were found. Conclusion. Pronounced dysbacteriosis with predominating opportunistic Klebsiella, enterobacteria, Proteus, and Staphylococcus aureus was observed in the large intestine of hypertensive patients with MS. The intestinal microbiome of patients with AH (without MS) was represented by normal microflora. Conditionally pathogenic Clostridium and Klebsiella also predominated in the oral cavity of patients with hypertension and MS. The microbiota of patients with AH without MS was more diverse with predominating normal flora.

Relationship between Metabolic Syndrome and its Diagnosis and Treatment of Hypertension Strategy

2011 ◽  
Vol 474-476 ◽  
pp. 211-214
Author(s):  
Xing Shou Pan ◽  
Zhao He Huang ◽  
Jing Sheng Lan
Keyword(s):  
Metabolic Syndrome ◽  
Cardiovascular Events ◽  
Oxidized Ldl ◽  
Integrated Control ◽  
Treatment Strategies ◽  
Hypertensive Patients ◽  
Treatment Of Hypertension ◽  
Close Relationship ◽  
Low Hdl ◽  
The Relationship

Explore the relationship between hypertension and metabolic syndrome, and treatment strategies. On the relationship between hypertension and metabolic syndrome were analyzed retrospectively, and how to conduct clinics for certain summary. Metabolic syndrome and hypertension exists a close relationship. Hypertensive patients with low HDL-C and high LDL-C level; whether oxidized LDL is high value or low value, MS group the incidence of cardiovascular disease is always higher than non-MS group. MS in blood pressure is an important component of integrated control of MS, can effectively prevent the occurrence of cardiovascular events and diabetes.

scholarly journals ASSOCIATIONS OF IRS-1 POLYMORPHISM WITH VARIOUS COMPONENTS OF THE METABOLIC SYNDROME IN HYPERTENSIVE PATIENTS

2019 ◽  
Vol 72 (8) ◽  
pp. 1494-1498
Author(s):  
Maryna Kochuieva ◽  
Valentyna Psarova ◽  
Larysa Ruban ◽  
Nataliia Kyrychenko ◽  
Olena Alypova ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Metabolic Syndrome ◽  
Waist Circumference ◽  
Glucose Tolerance ◽  
Arterial Hypertension ◽  
Abdominal Obesity ◽  
Healthy Individuals ◽  
Hypertensive Patients ◽  
The Metabolic Syndrome

Introduction: The metabolic syndrome is one of the most discussed cross-disciplinary problems of modern medicine. Now there are various definitions and criteria of diagnostics of metabolic syndrome. The abdominal obesity is considered the main component of the metabolic syndrome, as a reflection of visceral obesity which degree is offered to be estimated on an indirect indicator – a waist circumference. Alongside with abdominal obesity, a number of classifications distinguish insulin resistance (IR) as a diagnostic criterion of metabolic syndrome. It is proved that IR is one of the pathophysiological mechanisms influencing the development and the course of arterial hypertension (AH), type 2 DM and obesity. There are two components in the development of IR: genetic (hereditary) and acquired. In spite of the fact that IR has the accurate genetic predisposition, exact genetic disorders of its appearance have not been identified yet, thus demonstrating its polygenic nature. The aim: To establish possible associations of the insulin receptor substrate-1 (IRS-1) gene polymorphism with the severity of the metabolic syndrome components in patients with arterial hypertension (AH). Materials and methods: 187 patients with AH aged 45-55 years and 30 healthy individuals. Methods: anthropometry, reactive hyperemia, color Doppler mapping, biochemical blood analysis, HOMA-insulin resistance (IR), glucose tolerance test, enzyme immunoassay, molecular genetic method. Results: Among hypertensive patients, 103 had abdominal obesity, 43 - type 2 diabetes, 131 - increased blood triglycerides, 19 - decreased high density lipoproteins, 59 -prediabetes (33 - fasting hyperglycemia and 26 - impaired glucose tolerance), 126 had IR. At the same time, hypertensive patients had the following distribution of IRS-1 genotypes: Gly/Gly - 47.9%, Gly/Arg - 42.2% and Arg/Arg - 10.7%, whereas in healthy individuals the distribution of genotypes was significantly different: Gly/Gly - 86.8% (p<0.01), Gly/ Arg - 9.9% (p<0.01) and Arg/Arg - 3.3% (p<0.05). Hypertensive patients with Arg/Arg and Gly/Arg genotypes had significantly higher HOMA-IR (p<0.01), glucose, insulin and triglycerides levels (p<0.05), than in Gly/Gly genotype. At the same time, body mass index, waist circumference, blood pressure, adiponectin, HDL, interleukin-6, C-reactive protein, degree of endothelium-dependent vasodilation, as well as the frequency of occurrence of impaired glucose tolerance did not significantly differ in IRS-1 genotypes. Conclusions: in hypertensive patients, the genetic polymorphism of IRS-1 gene is associated with such components of the metabolic syndrome as hypertriglyceridemia and fasting hyperglycemia; it is not associated with proinflammatory state, endothelial dysfunction, dysglycemia, an increase in waist circumference and decrease in HDL.

scholarly journals Association of IL-6 Polymorphism -174G/C and Metabolic Syndrome in Hypertensive Patients

2015 ◽  
Vol 2015 ◽  
pp. 1-6 ◽  
Author(s):  
Andrei Alkmim Teixeira ◽  
Beata Marie Redublo Quinto ◽  
Maria Aparecida Dalboni ◽  
Cassio Jose de Oliveira Rodrigues ◽  
Marcelo Costa Batista
Keyword(s):  
Metabolic Syndrome ◽  
Framingham Risk Score ◽  
Total Population ◽  
Visceral Obesity ◽  
Binary Logistic Regression ◽  
Chain Reaction ◽  
Hypertensive Patients ◽  
Framingham Risk ◽  
High Prevalence ◽  
Polymerase Chain

Introduction. Visceral obesity, the central core of metabolic syndrome (MetS), is conceived as the pathogenic basis of an increased cardiovascular burden and is related with changes in cytokines. We investigated whether IL-6-174G/C gene polymorphism is associated with MetS prevalence in hypertensive patients.Method. A population of hypertensive patients was included and stratified by the presence of MetS according to IDF criteria and evaluated by Framingham risk score. The IL-6-174G/C genotyping was performed by polymerase chain reaction and the prevalence of MetS was compared between “C” carrier and “non-C” carrier groups.Results. From an original sample of 664 patients, 612 (34.2% men, age 57.3 ± 10.1, 30.4% diabetics) were included. MetS was diagnosed in 51.3% of total population and “C” carriers demonstrated high prevalence of MetS (P<0.05) and each of its components. On binary logistic regression, it was observed that the IL-6 polymorphism was independently associated with occurrence of MetS, even after adjusting for covariates (OR 1.13–2.37, 95% CI,P<0.05).Conclusion. The C allele at the -174 locus of IL-6 gene is independently associated with the occurrence of metabolic syndrome, emphasizing the importance of inflammatory genetic background in the pathogenesis of visceral obesity and related cardiovascular burden.

scholarly journals Myocardial hipertrophy in hypertensive patients with and without metabolic syndrome

2008 ◽  
Vol 65 (11) ◽  
pp. 830-834 ◽  
Author(s):  
Branislava Ivanovic ◽  
Dane Cvijanovic ◽  
Marija Tadic ◽  
Dragan Simic
Keyword(s):  
Blood Pressure ◽  
Metabolic Syndrome ◽  
Drug Treatment ◽  
Arterial Hypertension ◽  
Left Ventricular Mass ◽  
Left Ventricular ◽  
Control Group ◽  
Hypertensive Patients ◽  
Ventricular Mass ◽  
Significant Difference

Background/Aim. Beside arterial hypertension as the most important factor of a myocardial hypertension development, very important risk factors are obesity, hypercholesterolemia, insulin resistance, etc. The aim of the study was to examine the influence of metabolic syndrome (MetS) on left ventricular hypertrophy in patients with arterial hypertension. Methods. We checked medical records for 138 patients with arterial hypertension, and compared them with the control group of 44 normotensive subjects. The patients with arterial hypertension were divided into two groups considering the presence of MetS: with MetS (59 patients), and without MetS (79 patients). We defined MetS as presence of three (or more) within five criteria: central obesity (> 102 cm male, > 88 cm female), raised triglycerides (> 1.7 mmol/L, or drug treatment for elevated triglycerides), reduced high density lipoprotein (HDL) cholesterol (< 1.03 mmol/L male, < 1.3 mmol/L female), raised blood pressure (> 130 mmHg systolic, > 90 mmHg diastolic), raised fasting glucose (> 6.11 mmol/L, or drug treatment for elevated glucose level). In each group routine laboratory, echocardiography and 24-hour ambulatory blood pressure monitoring were performed. Results. We found statisticaly significant higher left ventricular mass in both subgroups hypertensive patients in comparison with the control group (p < 0.05). We did not find statistically significant difference (227.31?63.44 vs 219?59.5, p > 0.05) in left ventricular mass between these two groups of patients. In the patients with arterial hypertension and MetS we found hypertrophy more frequently than in the subgroup without MetS (43/57 vs 34/69, p < 0.001). Conclusion. Our results suggest that associated cardiometabolic risks increase the prevalence of myocardial hypertrophy, but do not influence left ventricular mass.

Prevalence of metabolic syndrome in never treated mood disordered patientss

2007 ◽  
Vol 30 (4) ◽  
pp. 95
Author(s):  
Valerie Taylor ◽  
Glenda M. MacQueen
Keyword(s):  
Metabolic Syndrome ◽  
Mood Disorders ◽  
Population Attributable Risk ◽  
Disease Process ◽  
Visceral Obesity ◽  
Premature Mortality ◽  
Overweight And Obesity ◽  
The Metabolic Syndrome ◽  
Increased Risk ◽  
Bipolar Patients

Bipolar disorder and major depression are life-shortening illnesses. Unnatural causes such as suicide and accidents account for only a portion of this premature mortality1 Research is beginning to identify that mood disordered patients have a higher incidence of metabolic syndrome, an illness characterized by dyslipidemia, impaired glucose tolerance, hypertension and obesity.2 Metabolic syndrome is associated with an increased risk for a variety of physical illnesses. Hypothesis: Never treated patients with mood disorders have preexisting elevations in the prevalence of the component variables of metabolic syndrome. Central obesity will be especially elevated, predicting increased premature mortality. Methods: We assessed never treated patients with mood disorders for metabolic syndrome and its component variables. Patients were assessed at baseline and followed up at 6-month intervals. All psychiatric pharmacotherapy was documented. Body mass index (BMI) was also obtained and the percentage of deaths attributable to overweight and obesity was calculated using the population attributable risk (PAR). [PAR= ∑[P (RR-1)/RR] Results: Prior to the initiation of treatment, patients did not differ from population norms with respect to metabolic syndrome or BMI. At 2-year follow-up, BMI had increased for unipolar patients 2.02 points and 1.92 points for bipolar patients. (p < .001) This increase in BMI predicted an increase in mortality of 19.4%. Conclusion: An increase in visceral obesity is often the first component of metabolic syndrome to appear and may indicate the initiation of this disease process prematurely in this group. The increase in BMI places patients with mood disorders at risk for premature mortality and indicates a need for early intervention. References 1.Osby U, Brandt L, Correia N, Ekbom A & Sparen P. Excess mortability in bipolar and Unipolar disorder rin Sweden. Archives of General Psychiatry, 2001;58: 844-850 2.Toalson P, Saeeduddin A, Hardy T & Kabinoff G. The metabolic syndrome in patients with severe mental illness. Journal of Clinical Psychiatry, 2004; 6(4): 152-158

Sign in / Sign up

Export Citation Format

Share Document